akr-501 has been researched along with Anemia--Aplastic* in 4 studies
1 review(s) available for akr-501 and Anemia--Aplastic
Article | Year |
---|---|
The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
Thrombopoietin regulates platelet production through activation of the thrombopoietin receptor (TPO-R). TPO-R agonists (TPO-RAs) are available to treat thrombocytopenia in chronic immune thrombocytopenia (ITP), chronic liver disease (CLD) patients who are undergoing a procedure, severe aplastic anemia (SAA), and hepatitis C virus (HCV) infection. There are four TPO-RAs approved in the US and Europe: romiplostim (ITP), eltrombopag (ITP, SAA, HCV), avatrombopag (ITP, CLD), and lusutrombopag (CLD). It is important to understand pharmacological characteristics of these agents when evaluating treatment options. Avatrombopag interacts with the transmembrane domain of the TPO-RA and does not compete with endogenous thrombopoietin for TPO-R binding. Structural differences between avatrombopag and other TPO-RAs may impart differential downstream effects on cell signaling pathways, potentially resulting in clinically relevant differences in outcome. Avatrombopag has a favorable pharmacological profile with similar exposure in Japanese, Chinese, or Caucasian patients and no drug-drug interactions, food interactions, or potential for chelation. Topics: Anemia, Aplastic; Hepatitis C; Humans; Liver Diseases; Receptors, Thrombopoietin; Thiazoles; Thiophenes; Thrombopoietin | 2022 |
3 other study(ies) available for akr-501 and Anemia--Aplastic
Article | Year |
---|---|
Avatrombopag is effective in patients with chemoradiotherapy-induced aplastic anemia: a single-center, retrospective study.
Aplastic anemia (AA) secondary to radiotherapy presents a difficult situation in the treatment of both the malignant tumor and AA itself. We aimed to evaluate the efficacy of avatrombopag (AVA), a thrombopoietin receptor agonist, in patients with AA secondary to chemoradiotherapy. In this retrospective study, patients with malignant tumors who were diagnosed with AA after radiotherapy and chemotherapy and accepted AVA between September 2020 and October 2021 at Peking Union Medical College Hospital were selected. A total of 34 patients were enrolled, including 13 (38.2%) men, with a median age of 60 (20-71) years. At a median of 8 (6-18) months of follow-up, the overall response rates (ORRs) at 1, 3, and 6 months were 32.4%, 55.9%, and 58.8%, respectively, and the complete response rates (CRRs) were 5.9%, 14.7%, and 23.5%, respectively. The median time to respond was 3 (1-6) months. In total, 15.0% of patients relapsed during follow-up, but no clonal evolution was noticed. Mild side effects were observed in 17.6% of patients without drug withdrawal. At the end of follow-up, 17.6% of patients had tumors relapsed. Four patients died, three from tumor relapse and one from cerebral hemorrhage. The ORR and CRR did not correlate with eltrombopag before AVA (p > 0.05) but increased when the total exposure of AVA increased (p = 0.011), and the threshold for AVA response was a cumulative dose > 3,000 mg (p = 0.013). AVA yielded good response and tolerance in patients treated for AA secondary to chemoradiotherapy, and a higher dose may correlate with better response. Topics: Aged; Anemia, Aplastic; Chemoradiotherapy; Female; Humans; Male; Middle Aged; Retrospective Studies; Thiazoles | 2023 |
Severe aplastic anemia in a patient with erythropoietic protoporphyria successfully treated by avatrombopag.
Topics: Anemia, Aplastic; Humans; Protoporphyria, Erythropoietic; Thiazoles; Thiophenes | 2022 |
[Avatrombopag combined with standard immunosuppressive therapy in the treatment of severe aplastic anemia with hepatic impairment in six patients].
Topics: Anemia, Aplastic; Antilymphocyte Serum; Cyclosporine; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Thiazoles | 2022 |